ABVX Abivax S.A. IFRS
Pharmaceutical Preparations · Nasdaq · SEC CIK 1956827 · Reporting currency EUR · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Unit: EUR | FY2025*2025-12-31 | FY2024*2024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | — |
| R&D expense | 177.76M | 146.53M |
| SG&A expense | 67.67M | 32.95M |
| Operating income | -246.06M | -172.98M |
| Interest expense | 111.74M | 16.99M |
| Pretax income | -330.25M | -176.24M |
| Income tax | 5.85M | 0 |
| Net income | -336.10M | -176.24M |
| EBITDA | -244.98M | -171.88M |
| EPS (basic) | -4.83 | -2.80 |
| EPS (diluted) | -4.83 | -2.80 |
| Weighted avg. shares (diluted) | 69.53M | 63.05M |
| Balance sheet | ||
| Cash & equivalents | 516.68M | 144.22M |
| Short-term investments | 0 | 136,000 |
| Current assets | 551.24M | 170.67M |
| PP&E, netmay include right-of-use assets (IFRS) | 2.09M | 2.67M |
| Goodwill | 18.42M | 18.42M |
| Intangibles | 6.61M | 6.61M |
| Total assets | 584.34M | 205.23M |
| Current liabilities | 63.02M | 94.00M |
| Total liabilities | 129.14M | 164.64M |
| Shareholders' equity | 455.20M | 40.58M |
| Shares outstanding | — | 63.35M |
| Cash flow statement | ||
| Operating cash flow | -161.13M | -154.07M |
| Capital expenditure | 142,000 | 640,000 |
| Free cash flow | -161.27M | -154.71M |
| Investing cash flow | -8.19M | 15.76M |
| Financing cash flow | 547.31M | 28.21M |
| Depreciation & amortization | 1.07M | 1.10M |
| Stock-based compensation | 35.40M | 20.22M |
Free plan shows the latest 2 periods; Pro shows all 5 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company does not report gross profit in XBRL.
· Amounts are in the company's reporting currency, EUR, not USD; the site does no currency conversion.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.